{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:49:58Z","timestamp":1788522598809,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41391-022-00517-6","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T19:02:36Z","timestamp":1646074956000},"page":"561-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Germline alterations among Hispanic men with prostate cancer"],"prefix":"10.1038","volume":"25","author":[{"given":"Elizabeth","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Shaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Madlensky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Javier-Desloges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick E.","family":"Millard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Kellogg","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0849-7018","authenticated-orcid":false,"given":"Kathryn E.","family":"Hatchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9205-3756","authenticated-orcid":false,"given":"Edward D.","family":"Esplin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Nussbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Weise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"517_CR1","unstructured":"Cancer.org. 2021. Key statistics for prostate cancer | prostate cancer facts. https:\/\/www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html. Accessed 27 Aug 2021."},{"key":"517_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.15585\/mmwr.mm6941a1","volume":"69","author":"DA Siegel","year":"2020","unstructured":"Siegel DA, O\u2019Neil ME, Richards TB, Dowling NF, Weir HK. Prostate cancer incidence and survival, by stage and race\/ethnicity\u2014United States, 2001\u20132017. MMWR Morb Mortal Wkly Rep. 2020;69:1473\u201380.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"517_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41391-018-0097-y","volume":"22","author":"RW Dobbs","year":"2019","unstructured":"Dobbs RW, Malhotra NR, Abern MR, Moreira DM. Prostate cancer disparities in Hispanics by country of origin: a nationwide population-based analysis. Prostate Cancer Prostatic Dis. 2019;22:159\u201367.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"517_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3322\/caac.21695","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ortiz AP, Pinheiro PS, Bandi P, Minihan A, Fuchs HE, et al. Cancer statistics for the US Hispanic\/Latino population, 2021. CA Cancer J Clin. 2021;71:466\u201387.","journal-title":"CA Cancer J Clin"},{"key":"517_CR5","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.3390\/ijms21145036","volume":"21","author":"A Brand\u00e3o","year":"2020","unstructured":"Brand\u00e3o A, Paulo P, Teixeira MR. Hereditary predisposition to prostate cancer: from genetics to clinical implications. Int J Mol Sci. 2020;21:5036.","journal-title":"Int J Mol Sci"},{"key":"517_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","volume":"315","author":"LA Mucci","year":"2016","unstructured":"Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016;315:68\u201376.","journal-title":"JAMA"},{"key":"517_CR7","doi-asserted-by":"publisher","first-page":"djw110.","DOI":"10.1093\/jnci\/djw110","volume":"108","author":"O Bratt","year":"2016","unstructured":"Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a nationwide population-based study. J Natl Cancer Inst. 2016;108:djw110.","journal-title":"J Natl Cancer Inst"},{"key":"517_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443\u201353.","journal-title":"N Engl J Med"},{"key":"517_CR9","unstructured":"[Guideline] Prostate Cancer. National Comprehensive Cancer Network. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Version 3.2020. 2020. Accessed 9 Dec 2021."},{"issue":"10504","key":"517_CR10","first-page":"15","volume":"39","author":"ED Esplin","year":"2021","unstructured":"Esplin ED, Cahn DJ, Mazzarella B, Pieczonka CM, Gazi M, Belkoff LH, et al. Underdiagnosis of germline genetic prostate cancer: are genetic testing guidelines an aid or an impediment?. J Clin Oncol. 2021;39 10504:15.","journal-title":"J Clin Oncol"},{"key":"517_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","volume":"5","author":"P Nicolosi","year":"2019","unstructured":"Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O\u2019Leary E, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019;5:523\u20138.","journal-title":"JAMA Oncol"},{"issue":"e1","key":"517_CR12","first-page":"7","volume":"80","author":"DHK Kwon","year":"2020","unstructured":"Kwon DHK, Borno HT, Cheng HH, Zhou AY, Small EJ. Ethnic disparities among men with prostate cancer undergoing germline testing. Urol Oncol. 2020:80.e1\u20137.","journal-title":"Urol Oncol"},{"key":"517_CR13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/pros.23739","volume":"79","author":"VN Giri","year":"2019","unstructured":"Giri VN, Hegarty SE, Hyatt C, O\u2019Leary E, Garcia J, Knudsen KE, et al. Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing. Prostate. 2019;79:333\u20139.","journal-title":"Prostate"},{"key":"517_CR14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ygyno.2018.04.309","volume":"149","author":"PN Kamath","year":"2018","unstructured":"Kamath PN, Schlumbrecht MP, George S, Slomovitz BM, Koru-Sengul T, Miao F, et al. Identifying disparities in germline and somatic testing in patients with ovarian cancer in a University Health System. Gynecol Oncol. 2018;149:134.","journal-title":"Gynecol Oncol"},{"key":"517_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/GIM.0b013e3182091ba4","volume":"13","author":"DE Levy","year":"2011","unstructured":"Levy DE, Byfield SD, Comstock CB, Garber JE, Syngal S, Crown WH, et al. Underutilization of BRCA1\/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk. Genet Med. 2011;13:349\u201355.","journal-title":"Genet Med"},{"key":"517_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3322\/canjclin.54.2.78","volume":"54","author":"E Ward","year":"2004","unstructured":"Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A, et al. Cancer disparities by race\/ethnicity and socioeconomic status. CA Cancer J Clin. 2004;54:78\u201393.","journal-title":"CA Cancer J Clin"},{"key":"517_CR17","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J Bono","year":"2020","unstructured":"Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"517_CR18","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida W, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38:3763\u201372.","journal-title":"J Clin Oncol"},{"key":"517_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"517_CR20","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","volume":"7","author":"NJ Samadder","year":"2021","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L, Rhodes D, Wick M, Okuno S, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7:230\u20137.","journal-title":"JAMA Oncol"},{"key":"517_CR21","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/gim.2017.37","volume":"19","author":"K Nykamp","year":"2017","unstructured":"Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, et al. Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. Genet Med. 2017;19:1105\u201317.","journal-title":"Genet Med"},{"key":"517_CR22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1089\/gtmb.2013.1548","volume":"17","author":"K Saulsberry","year":"2013","unstructured":"Saulsberry K, Terry SF. The need to build trust: a perspective on disparities in genetic testing. Genet Test Mol Biomark. 2013;17:647\u20138.","journal-title":"Genet Test Mol Biomark"},{"key":"517_CR23","first-page":"267","volume":"22","author":"B Glenn","year":"2012","unstructured":"Glenn B, Chawla N, Bastani R. Barriers to genetic testing for breast cancer risk among ethnic minority women: an exploratory study. Ethnicity Dis. 2012;22:267\u201373.","journal-title":"Ethnicity Dis"},{"key":"517_CR24","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1200\/JCO.2019.37.15_suppl.6593","volume":"37","author":"SJ Hsiao","year":"2019","unstructured":"Hsiao SJ, Sirecy A, Pendrick D, Freeman C, Yang J, Schwartz GK. Clinical utility and reimbursement for expanded genomic panel testing in adult oncology. J Clin Oncol. 2019;37:6593.","journal-title":"J Clin Oncol"},{"issue":"15_","key":"517_CR25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1200\/JCO.2020.38.15_suppl.1507","volume":"38","author":"HQ Rana","year":"2020","unstructured":"Rana HQ, Stopfer JE, Petrucelli N, Koeller DR, Pirzadeh-Miller S, Reys B, et al. A randomized controlled trial of video-education or in-person genetic counseling for men with prostate cancer (ProGen). J Clin Oncol. 2020;38 15_1507.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1038\/s41391-022-00539-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000}}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00517-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00517-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00517-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T14:08:53Z","timestamp":1660745333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-022-00517-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1038\/s41391-022-00517-6","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41391-022-00539-0","asserted-by":"object"}]},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"10 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41391-022-00539-0","URL":"https:\/\/doi.org\/10.1038\/s41391-022-00539-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RRM received research funding from Bayer, Pfizer, Tempus; serves on Advisory Board for AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Exelixis, Janssen, Merck, Novartis, Pfizer, Sanofi, Tempus; is a consultant for Dendreon, Myovant, Sorrento Therapeutics, Vividion; serves on the molecular tumor board at Caris. RLN is a consultant and stockholder in Maze Therapeutics and Genome Medical and a consultant for Pfizer Pharmaceuticals. SMN, KEH, EDE, and RLN are employees and stockholders of Invitae.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}